Summary of recent progress in the field of diabetes research (02.07)
February 07, 2018 Source: WuXi PharmaTech
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];1. Possible sharing mechanisms for type 1 diabetes complications in the eye and heart
In patients with type 1 diabetes, hyperglycemia may eventually damage blood vessels in the eyes, kidneys, heart, and other organs, but damage in different organs may be caused by different mechanisms. Recently, one of the world's largest diabetes research centers, the Joslin Diabetes Center in Massachusetts, found that the mechanism of damage to hyperglycemia in the eyes and heart may be similar, which is expected to promote complications. Treatment. The paper was published in the journal Diabetes Care.
The leading cause of death in patients with type 1 diabetes is cardiovascular disease (CVD). In the Joslin 50-year Medalist study, researchers studied patients with type 1 diabetes for 50 years or longer and examined CVD with chronic kidney disease (CKD) and proliferative diabetic retinopathy (proliferative). Correlation of diabetic retinopathy, PDR). The investigators found that patients with CKD had a higher risk of developing cardiovascular disease, and that the patient's PDR status was also independently associated with the risk of cardiovascular disease. The result was validated by another cohort of type 1 diabetes in Finland.
The study conducted a characterization of a US resident (n=762) with type 1 diabetes for 50 years or more at a single study site, through questionnaires, clinical follow-up, ophthalmic clinic examinations, and laboratory studies, and used from Finland. The replication cohort of the Diabetic Nephrology Study (FinnDiane) was verified (n=675). In the study, CKD was defined as an estimated glomerular filtration rate <45 mL/min/1.73 m2 (CKD stage 3b), PDR was defined according to the Early Treatment of Diabetic Retinopathy Study (ETDRS), and CVD was based on a questionnaire And/or hospital discharge registration records. The association of CVD status with CKD and PDR was analyzed by multivariate logistic regression.
The results showed that in patients with +CKD/-PDR (n=30) and -CKD/+PDR (n=339), the prevalence of CVD was half that of patients with +CKD/+PDR (n=66) ( 34.5% and 42.8% vs. 68.2%, p=0.002). PDR status in patients with CKD was independently associated with CVD (odd ratio 0.21 [95% CI 0.08-0.58], p=0.003). In the Finnish cohort, a lower incidence of CVD was also observed in +CKD/-PDR (n=21) compared to +CKD/+PDR (n=170) (19.1% versus 37.1%, p=0.10).
â–² Dr. George King (Source: Joslin Diabetes Center)
“This is an unexpected discovery,†said Dr. George King, senior vice president and chief scientific officer of the Joslin Diabetes Center, a professor at Harvard Medical School. “This suggests that biological factors related to vascular injury may be in the eye and cardiovascular system. Acts with the same mechanism, but may vary in the kidneys."
2. DexCom continuous blood glucose monitoring system test results are excellent
Recently, DexCom, Calif., released a positive result from a clinical trial comparing DexCom's G5 mobile continuous glucose monitoring system with a recently approved glucose monitoring system. . The positive results of the trial were published in Diabetic Medicine.
For people with diabetes, keeping abreast of blood sugar levels can help them avoid severe blood sugar fluctuations and their serious consequences. DexCom's G5 system provides real-time glucose readings for patients with type 1 or type 2 diabetes every five minutes, and glucose data can be shared to mobile devices for access anytime, anywhere. The G5 system is the first continuous glucose monitoring system approved for use in adults and pediatric patients aged 2 years and older.
The study, entitled "I-Hart," recruited 40 patients with type 1 diabetes for 8 weeks. The data showed that DexCom's G5 device reduced the patient's time to hypoglycemia by 43 minutes, while the other system increased the patient's time to hypoglycemia by 19 minutes. The trial also showed that the G5 system shortened the patient's nocturnal hypoglycemia time by 24 minutes, while the other system increased the patient's nighttime hypoglycemia time by 9 minutes.
â–² Mr. John Lister, General Manager of EMEA of DexCom (Source: DexCom)
“We are pleased that DexCom's G5 system significantly reduces the time of hypoglycemia during the day and night, thus reducing the fear associated with hypoglycemia,†commented John Lister, General Manager of DexCom EMEA (Europe, Middle East and Africa). "This study also helps demonstrate the value of a real-time continuous glucose monitoring system, helping people manage diabetes around the clock with reminders and alerts."
3. Follicum discovers potential new targets for diabetes treatment
Follicum has announced that it has successfully identified receptors that bind to peptides in insulin-secreting cells. The discovery is an important milestone in the company's ongoing diabetes program and opens up the potential to stimulate insulin secretion and reduce diabetes complications by targeting the receptor.
The study was conducted by Follicum in collaboration with Dualsystems Biotech, a Swiss-specialized proteomics, to identify receptors in insulin-secreting cell lines that bind to Follicum's peptides. The purpose of the experiment also included the analysis and optimization of the structure of the polypeptide for screening new drug candidates. Experiments have confirmed the presence of receptors, and they have the potential to become a new drug target for Follicum in the treatment of diabetes. The company will conduct preclinical research on the receptor at the Clinical Research Center at Lund University.
â–² Dr. Jan Alenfall, CEO of Follicum (Source: Follicum)
Dr. Jan Alenfall, CEO of Follicum, commented: “Our diabetes project has discovered this receptor, and we look forward to further research to pave the way for the development of new diabetes drugs. We have recently strengthened our organization, we are very I look forward to continuing to work with Lund University."
Reference material
[1] Eye and heart complications are tightly linked in type 1 diabetes
[2] Differential Association of Microvascular Attributions With Cardiovascular Disease in Patients With Long Duration of Type 1 Diabetes.
[3] Dexcom Beats Abbott in Head-to-Head Glucose Monitoring Trial
[4] https://
[5] Dexcom takes on Abbott in head-to-head glucose monitoring trial
[6] Follicum Identifies Receptors in Insulin-Producing Cells for Potential New Class of Diabetes Drugs
Original Title: Summary of Recent Progress in Diabetes Research (No. 50)
Foot Spa Massager,Bath Foot Massager Machine,Foot Spa Bath,Bath Foot Massager With Bubble
Huaian Mimir Electric Appliance Co., LTD , https://www.mimirfootbath.com